News

Alfa Wassermann buys licence
Enlarge image

BusinessItaly

Alfa Wassermann buys licence

05.10.2012 - Italian Alfa Wassermann has acquired an exclusive licence for Theravance’s serotonin 5-HT4 agonist velusetrag.

The US biotech partner can bag up to US$63.5 plus royalties for the exclusive development and commercialisation rights of the treatment for gastrointestinal motility disorders such as constipation, irritable bowel syndrome, functional dyspepsia, and gastroparesis. The Bologna-headquartered pharma firm Alfa Wassermann, will fund Phase II clinical trials and grant Theravance a US$10m option fee payable if Alfa Wassermann exercises its option for Europe, Russia, China,  and other key markets after clinical proof-of-concept. The San Francisco-based biotech firm also is set to receive development, regulatory and sales milestone payments of up to US$53.5m. Additionally it may earn royalties on net sales of velusetrag (TD-5108) up to 20%.

What makes velusetrag so attractive to the Italians is its, up-to-now, beneficial safety profile. Previous treatments for gastrointestinal (GI) dysmotility targeting the 5-hydroxytryptamine(4) receptor, modified the function of the cardiac HERG potassium channel leading to severe adverse effects. Within the Phase II programme, the Italian firm will evaluate the efficacy, safety and tolerability of once-daily oral velusetrag in the treatment of patients with gastroparesis. The disorder has few therapeutic options and it is characterised by delayed gastric emptying in the absence of a mechanical obstruction with symptoms that include early satiety, nausea, vomiting and bloating. Velusetrag has been shown to accelerate gastric emptying in healthy volunteers.

Theravance will retain the full rights to the drug in the US, Canada, Japan and certain other countries. The US firm has completed a 400-patient Phase II proof-of-concept study in chronic idiopathic constipation for the drug. In the trial the compound demonstrated statistically significant prokinetic activity at all three doses (15 mg, 30 mg, and 50 mg) tested.

It was generally well tolerated and showed a low incidence of adverse events at the two lowest doses.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/alfa-wasserman-buys-theravance-licence.html

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.40 EUR11.63%
  • SARTORIUS113.95 EUR4.93%
  • EVONIK27.85 EUR3.69%

FLOP

  • ADDEX3.30 CHF-4.07%
  • BIOFRONTERA1.95 EUR-3.47%
  • MEDIGENE3.70 EUR-2.63%

TOP

  • CYTOS0.33 CHF43.5%
  • ADDEX3.30 CHF42.2%
  • FORMYCON14.30 EUR41.9%

FLOP

  • BIOFRONTERA1.95 EUR-15.2%
  • ACTELION100.20 CHF-13.8%
  • MOLOGEN5.60 EUR-11.8%

TOP

  • SANTHERA105.50 CHF2570.9%
  • WILEX1.96 EUR168.5%
  • BB BIOTECH256.75 EUR98.6%

FLOP

  • CYTOS0.33 CHF-90.9%
  • MOLOGEN5.60 EUR-51.0%
  • 4SC0.82 EUR-50.9%

No liability assumed, Date: 29.01.2015